Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. Signal., 21 April 2009
Vol. 2, Issue 67, p. pe24
[DOI: 10.1126/scisignal.267pe24]

PERSPECTIVES

The Pharmacology of mTOR Inhibition

David A. Guertin1 and David M. Sabatini1,2,3*

1 Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02141, USA.
2 Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
3 Koch Center for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.

Abstract: A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)–based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.

* Corresponding author. Telephone, 617-258-6407; e-mail, sabatini{at}wi.mit.edu

Citation: D. A. Guertin, D. M. Sabatini, The Pharmacology of mTOR Inhibition. Sci. Signal. 2, pe24 (2009).

Read the Full Text

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of Rapamycin.
M. Hidalgo (2012)
J. Clin. Oncol. 30, 85-87
   Full Text »    PDF »
Autophagy activation by rapamycin reduces severity of experimental osteoarthritis.
B. Carames, A. Hasegawa, N. Taniguchi, S. Miyaki, F. J. Blanco, and M. Lotz (2011)
Ann Rheum Dis
   Abstract »    Full Text »
Multimodal Biomarker Investigation on Efficacy and Mechanism of Action for the Mammalian Target of Rapamycin Inhibitor, Temsirolimus, in a Preclinical Mammary Carcinoma OncoMouse Model: A Translational Medicine Study in Support for Early Clinical Development.
X. Wang, Y. Zhan, L. Zhao, J. Alvarez, I. Chaudhary, B.-B. Zhou, R. T. Abraham, and G. Z. Feuerstein (2011)
J. Pharmacol. Exp. Ther. 339, 421-429
   Abstract »    Full Text »    PDF »
Oncogenic EGFR Signaling Activates an mTORC2-NF-{kappa}B Pathway That Promotes Chemotherapy Resistance.
K. Tanaka, I. Babic, D. Nathanson, D. Akhavan, D. Guo, B. Gini, J. Dang, S. Zhu, H. Yang, J. De Jesus, et al. (2011)
Cancer Discovery 1, 524-538
   Abstract »    Full Text »    PDF »
S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation.
J. E. Aslan, G. W. Tormoen, C. P. Loren, J. Pang, and O. J. T. McCarty (2011)
Blood 118, 3129-3136
   Abstract »    Full Text »    PDF »
Pharmacological and Genetic Evaluation of Proposed Roles of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK), Extracellular Signal-regulated Kinase (ERK), and p90RSK in the Control of mTORC1 Protein Signaling by Phorbol Esters.
B. D. Fonseca, T. Alain, L. K. Finestone, B. P. H. Huang, M. Rolfe, T. Jiang, Z. Yao, G. Hernandez, C. F. Bennett, and C. G. Proud (2011)
J. Biol. Chem. 286, 27111-27122
   Abstract »    Full Text »    PDF »
mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop.
M. Keniry and R. Parsons (2011)
Cancer Discovery 1, 203-204
   Abstract »    Full Text »    PDF »
mTOR Kinase Domain Phosphorylation Promotes mTORC1 Signaling, Cell Growth, and Cell Cycle Progression.
B. Ekim, B. Magnuson, H. A. Acosta-Jaquez, J. A. Keller, E. P. Feener, and D. C. Fingar (2011)
Mol. Cell. Biol. 31, 2787-2801
   Abstract »    Full Text »    PDF »
mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells.
E. A. Goncharova, D. A. Goncharov, H. Li, W. Pimtong, S. Lu, I. Khavin, and V. P. Krymskaya (2011)
Mol. Cell. Biol. 31, 2484-2498
   Abstract »    Full Text »    PDF »
Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling.
Y. Yu, S.-O. Yoon, G. Poulogiannis, Q. Yang, X. M. Ma, J. Villen, N. Kubica, G. R. Hoffman, L. C. Cantley, S. P. Gygi, et al. (2011)
Science 332, 1322-1326
   Abstract »    Full Text »    PDF »
Utility of mTOR Inhibition in Hematologic Malignancies.
A. Younes and N. Samad (2011)
Oncologist 16, 730-741
   Abstract »    Full Text »    PDF »
Transcriptional Control of Cellular Metabolism by mTOR Signaling.
J. L. Yecies and B. D. Manning (2011)
Cancer Res. 71, 2815-2820
   Abstract »    Full Text »    PDF »
Engineering the ABA Plant Stress Pathway for Regulation of Induced Proximity.
F.-S. Liang, W. Q. Ho, and G. R. Crabtree (2011)
Science Signaling 4, rs2
   Abstract »    Full Text »    PDF »
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors.
E. Vilar, J. Perez-Garcia, and J. Tabernero (2011)
Mol. Cancer Ther. 10, 395-403
   Abstract »    Full Text »    PDF »
mTOR-Dependent Regulation of PHLPP Expression Controls the Rapamycin Sensitivity in Cancer Cells.
J. Liu, P. D. Stevens, and T. Gao (2011)
J. Biol. Chem. 286, 6510-6520
   Abstract »    Full Text »    PDF »
Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F.
R. Cencic, D. R. Hall, F. Robert, Y. Du, J. Min, L. Li, M. Qui, I. Lewis, S. Kurtkaya, R. Dingledine, et al. (2011)
PNAS 108, 1046-1051
   Abstract »    Full Text »    PDF »
New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target?.
T. F. Cloughesy and P. S. Mischel (2011)
Clin. Cancer Res. 17, 6-11
   Abstract »    Full Text »    PDF »
AP-1 Regulates Cyclin D1 and c-MYC Transcription in an AKT-Dependent Manner in Response to mTOR Inhibition: Role of AIP4/Itch-Mediated JUNB Degradation.
R. Vartanian, J. Masri, J. Martin, C. Cloninger, B. Holmes, N. Artinian, A. Funk, T. Ruegg, and J. Gera (2011)
Mol. Cancer Res. 9, 115-130
   Abstract »    Full Text »    PDF »
Mammalian target of rapamycin: Biological function and target for novel anticancer agents.
E. B. Borders, C. Bivona, and P. J. Medina (2010)
Am. J. Health Syst. Pharm. 67, 2095-2106
   Abstract »    Full Text »    PDF »
Target of Rapamycin Signaling in Leukemia and Lymphoma.
C. Vu and D. A. Fruman (2010)
Clin. Cancer Res. 16, 5374-5380
   Abstract »    Full Text »    PDF »
Regulation of Mammalian Autophagy in Physiology and Pathophysiology.
B. Ravikumar, S. Sarkar, J. E. Davies, M. Futter, M. Garcia-Arencibia, Z. W. Green-Thompson, M. Jimenez-Sanchez, V. I. Korolchuk, M. Lichtenberg, S. Luo, et al. (2010)
Physiol Rev 90, 1383-1435
   Abstract »    Full Text »    PDF »
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony.
K. G. Foster and D. C. Fingar (2010)
J. Biol. Chem. 285, 14071-14077
   Abstract »    Full Text »    PDF »
Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases.
M. Renna, M. Jimenez-Sanchez, S. Sarkar, and D. C. Rubinsztein (2010)
J. Biol. Chem. 285, 11061-11067
   Abstract »    Full Text »    PDF »
mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action.
G. A. Soliman, H. A. Acosta-Jaquez, E. A. Dunlop, B. Ekim, N. E. Maj, A. R. Tee, and D. C. Fingar (2010)
J. Biol. Chem. 285, 7866-7879
   Abstract »    Full Text »    PDF »
The PI3K Pathway As Drug Target in Human Cancer.
K. D. Courtney, R. B. Corcoran, and J. A. Engelman (2010)
J. Clin. Oncol. 28, 1075-1083
   Abstract »    Full Text »    PDF »
Regulation of mTOR Complex 1 (mTORC1) by Raptor Ser863 and Multisite Phosphorylation.
K. G. Foster, H. A. Acosta-Jaquez, Y. Romeo, B. Ekim, G. A. Soliman, A. Carriere, P. P. Roux, B. A. Ballif, and D. C. Fingar (2010)
J. Biol. Chem. 285, 80-94
   Abstract »    Full Text »    PDF »
Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer.
P. Gulhati, Q. Cai, J. Li, J. Liu, P. G. Rychahou, S. Qiu, E. Y. Lee, S. R. Silva, K. A. Bowen, T. Gao, et al. (2009)
Clin. Cancer Res. 15, 7207-7216
   Abstract »    Full Text »    PDF »
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span.
C. Selman, J. M. A. Tullet, D. Wieser, E. Irvine, S. J. Lingard, A. I. Choudhury, M. Claret, H. Al-Qassab, D. Carmignac, F. Ramadani, et al. (2009)
Science 326, 140-144
   Abstract »    Full Text »    PDF »
Site-Specific mTOR Phosphorylation Promotes mTORC1-Mediated Signaling and Cell Growth.
H. A. Acosta-Jaquez, J. A. Keller, K. G. Foster, B. Ekim, G. A. Soliman, E. P. Feener, B. A. Ballif, and D. C. Fingar (2009)
Mol. Cell. Biol. 29, 4308-4324
   Abstract »    Full Text »    PDF »
Striking the balance between PTEN and PDK1: it all depends on the cell context.
A. Iwanami, T. F. Cloughesy, and P. S. Mischel (2009)
Genes & Dev. 23, 1699-1704
   Abstract »    Full Text »    PDF »
Thwarting Dyskinesia by Targeting mTORC1.
E. Klann (2009)
Science Signaling 2, pe42
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 21 April 2009.
M. B. Yaffe and A. M. VanHook (2009)
Science Signaling 2, pc8
   Abstract »    Full Text »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882